来源：中国新闻网 图为论坛现场。雷键 摄 中国科学院院士、陆军军医大学第一附属医院病理科主任、金凤实验室主任卞修武表示，金凤智慧病理 中心依赖病理、影像、检验、临床、人工智能等专家资源，依托金凤实验室有组织地开展集中攻关，目 标是促进病理诊断精准化与治疗决策普惠化。金凤实验室将有计划、有步骤地推进金凤智慧病理中心建 设，并发起"千万级泛病种标准化病理数据库计划"，支撑样本和数据模块建设；打造"金凤病理智能标 算平台"，支撑平台和工具模块建设。 金凤实验室副主任徐辉表示，"千万级泛病种标准化病理数据库计划"由金凤实验室联合8家市外医疗机 构、市内12家医疗机构共同发起，将整合人体9大系统、5种主要病理类型疾病数据，建立覆盖病理图 像、诊断报告、临床文本的泛病种病理数据集以及多模态标准化数据集，形成功能强大的数据基座，同 时构建脑肿瘤病理样本及数据全流程标准化体系，为AI诊疗产品研发提供高质量数据资源支持。 此外，"重庆先进病理研究院"和"重庆市医学生物样本数据资源库"在论坛上正式揭牌。(完) 中新网重庆4月18日电 (梁钦卿)以"AI赋能病理·智启健康未来"为主题的智慧病理发展论坛17日在重庆举 行。来自全国病 ...

Summary of Conference Call Notes Company Overview - The company discussed is Yidu Technology, a pioneering innovator in the AI healthcare industry with a focus on deepening its expertise over the past decade [1][2]. Key Points and Arguments Industry and Data - Yidu Technology has accumulated 5.5 billion high-quality medical records, covering over 1.1 billion patient visits, which is a significant asset in the Chinese healthcare landscape where data is not typically available post-discharge [1][20]. - The company has developed a comprehensive disease knowledge graph that encompasses all known diseases, supported by various specialized datasets and models [2][19]. Product and Application - The company offers a range of products, including a project management platform and an AI middle platform, which have seen accelerated project orders and implementations since the Chinese New Year, with over 20 projects currently in progress [3][4]. - The AI middle platform integrates multiple open-source models and has already been implemented in several hospitals, demonstrating its practical application in real-world settings [3][10]. Market Position and Competition - Yidu Technology is positioned as a key player in the AI healthcare market, with a belief that the market is still in its early stages and not yet saturated with competition [8][24]. - The company emphasizes that its competitive edge lies in its extensive data accumulation, algorithmic depth, and application scenarios, which are superior to many competitors in the field [20][33]. Financial Performance and Growth - The company anticipates a 10% annual growth in paid services, with a current coverage of 2,800 hospitals, including 105 top-tier hospitals and over 40 regulatory government clients [4][29]. - There is an expectation of improved financial performance and profitability sooner than previously guided, with a focus on enhancing the gross margin through product mix adjustments [29][30]. Collaboration and Partnerships - Yidu Technology has established a deep partnership with Huawei, leveraging their chip technology and exploring further collaboration opportunities in the healthcare sector [6][7]. - The company is also exploring partnerships with various hospitals and government projects, indicating a robust pipeline of collaborative opportunities [9][16]. Challenges and Future Outlook - The company acknowledges challenges in expanding into lower-tier hospitals due to budget constraints but sees potential for future growth as technology costs decrease and demand for intelligent healthcare solutions increases [41][43]. - There is a strong belief that the AI healthcare market will continue to grow, driven by policy support and increasing hospital budgets for technology investments [16][17]. Miscellaneous Insights - The company has noted a significant increase in project budgets from hospitals and government clients, with some budgets rising from millions to tens of millions [16][17]. - Yidu Technology's AI capabilities are designed to assist in various clinical scenarios, including complex cases, showcasing the versatility and depth of its technology [12][36]. Conclusion Yidu Technology is positioned as a leader in the AI healthcare sector, with a strong foundation of data, innovative products, and strategic partnerships. The company is optimistic about future growth, driven by increasing demand for intelligent healthcare solutions and supportive policies.

据介绍，"镜观"是全球首个深度融合大数据、AI技术与医疗资源的消化内镜全场景智能体，由复旦大学 附属中山医院等研发，通过整合超百万例内镜影像，构建消化内镜多模态基础模型，并依托国产自主 AI芯片实现医院端侧安全部署，形成"感知-决策-执行-进化"的完整智能链。 "镜观"可以成为患者的私人医疗顾问，除了一对一详细解读报告、答疑解惑之外，还可以通过知识图谱 及专病数据库，深入解读疾病相关情况，进一步实现预防科普和健康宣传等功能。它可以是医生的"手 术智囊伙伴"，医生可以通过"镜观"搭载的眼动和语音交互功能，在手术中实时获取病灶分析。同 时，"镜观"还能自动生成结构化报告，医生只需要查缺补漏和最终确认，文书时间可至少缩短至 50%。"镜观"还搭载了诊疗规范库，能智能预警操作风险，为基层医生提供三甲级水平的实时指导。 此外，"镜观"还是辅助医院管理决策的"科室大管家"，系统基于国产AI算力平台开发，通过"管理驾驶 舱"进行数据资源整合、智能分析，实现科室运转的精准调控。在安全性方面，做到了"数据不出院"的 安全架构，也使得"镜观"可在基层医院快速部署。据透露，未来三年，该平台计划接入全国300家医疗 机构，培训200 ...

NO.2 广东省交通行业算力中心揭牌 4月9日，广东省交通行业算力中心在韶关市揭牌。广东省交通行业算力中心是"广东省交通行业高精数 字底座"的关键基础设施，是广东省"一轴两网"公路水路交通基础设施数字化转型升级实施方案的重点 工程，由广东省交通集团负责建设。该中心按照国家A级机房标准建设，规划部署638个标准机柜，首 期建成324个机柜，可满足全省交通行业超算、云计算、大数据分析等多样化算力需求。 每经记者 杨煜 每经编辑 马子卿 丨2025年4月10日 星期四丨 NO.1 联影发布"元智"医疗大模型 4月9日，联影发布"元智"医疗大模型，并同步推出覆盖影像诊断、临床治疗、医学科教、医院管理、患 者服务等多场景的10余款医疗智能体。其中，基于数千万级医疗影像数据和数十万级医疗级精细标注数 据训练打造的"元智"医疗影像大模型能支持10+影像模态、300种影像处理任务，在处理诸如复杂病灶诊 断，器官分割等关键任务上，模型的精准度测评已超过95%。 点评：医疗AI向临床深水区突破，95%的精准度或重构诊疗效率标准，加速医疗资源普惠化。但数据隐 私安全、伦理审查及医患信任建立仍是落地难点，投资者需关注技术向实际创收转 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 一、募集资金基本情况 开发行可转换公司债券，募集资金总额为 543,310,000.00 元，扣除承销保荐费 （一）2018年非公开 用及与本次可转换公司债券发行直接相关的其他发行费用（不含增值税）后的 经中国证券监督管理委员会核发的《关于核准武汉塞力斯医疗科技股份有限公司非公开发行股票的批 复》（证监许可[2017]2322号）核准，塞力斯医疗科技集团股份有限公司（以下简称"公司"）于2018年 6月5日非公开发行A股股票26,853,709股，每股面值1元，发行价格为每股人民币23.31元，募集资金总额 为625,959,956.79元，扣除各项发行费用后实际募集资金净额人民币607,608,016.80元。上述资金已于 2018年6月5日全部到位，并经中审众环会计师事务所（特殊普通合伙）于2018年6月5日出具的众环验字 （2018）010040号验资报告审验。 募集资金净额为人民币 533,298,679.25 元。上述资金已于 2020 年 8 月 27 日全部到 ...

Core Viewpoint - The company, Suzhou Medistone Medical Technology Co., Ltd., is facing financial challenges with a significant net loss reported in the latest quarterly results, despite a slight increase in revenue. The stock has also seen a decline in value, indicating potential investor concerns. Company Overview - Suzhou Medistone specializes in providing Clinical Information Systems (CIS) and overall clinical information solutions, with its core product, the DoCare series, covering critical areas such as operating rooms and emergency services [2] - The company serves over 2,400 medical institutions across 32 provinces in China, including nearly 1,200 tertiary hospitals, showcasing its extensive market reach [2] - Medistone is recognized as a national high-tech enterprise with a strong emphasis on technological innovation, holding nearly 600 intellectual property rights [2] Financial Performance - For the third quarter of 2024, the company reported a revenue of 360 million yuan, reflecting a year-on-year increase of 2.93% [3] - The net profit for the same period was a loss of approximately 167.22 million yuan, representing a year-on-year decline of 81.64% [3] - The gross profit margin stood at 12.87%, indicating challenges in maintaining profitability [3] Market Position - The company's stock closed at 11.02 yuan, down 7.00%, with a latest price-to-book ratio of 3.68 and a total market capitalization of 3.375 billion yuan [1] - The company is compared to industry averages, with a trailing PE ratio of -9.80, indicating negative earnings, contrasting with the industry average of 130.24 [4]

Group 1 - The Hang Seng Biotechnology Index (HSHKBIO) has seen a strong increase of 3.70% as of April 1, 2025, with notable gains from constituent stocks such as Kangfang Biotech (09926) up 8.14%, and others like Hong Kong Medicine (00013) and Rongchang Biotech (09995) also showing significant increases [1] - The Hang Seng Biotechnology ETF (513280) rose by 4.18%, reaching a latest price of 0.9 HKD, with a trading volume of 37.5587 million HKD and a turnover rate of 13.91%, indicating active market participation [1] - The latest scale of the Hang Seng Biotechnology ETF reached 262 million HKD, marking a new high for the year, with the number of shares also hitting a recent high of 305 million [1] Group 2 - Kangfang Biotech reported a sales revenue exceeding 2 billion HKD for 2024, reflecting a year-on-year growth of 25%, driven by strong performance in new drug sales [2] - Domestic innovative drugs are entering a harvest period, with 39 new drugs approved in China in 2024, accounting for nearly 40% of global approvals, and 24% of first-in-class drugs in development being from Chinese companies [2] - The overall performance of leading innovative pharmaceutical companies is improving, with many approaching profitability due to mature R&D and sales systems [2] Group 3 - The 2024 Government Work Report indicates an optimization of drug procurement policies, shifting from a price-only focus to a balance of quality and cost, which is expected to benefit leading pharmaceutical companies [3] - The upcoming 11th batch of drug procurement in 2025 is anticipated to enhance quality assessment and regulatory measures, potentially leading to a consolidation of market share among compliant leading pharmacies [3] - The number of retail pharmacies closing has increased to 13,700 by Q4 2024, suggesting a gradual improvement in the competitive landscape for leading pharmacies [3] Group 4 - The Hang Seng Biotechnology ETF (513280) is noted for having the lowest fee rate in the Hong Kong innovative drug market, with a management fee of only 0.15% per year, significantly lower than similar products [4] - As of December 2024, the ETF's index composition includes 66.4% innovative drugs, 15.4% CXO, and over 9% in pharmaceutical distribution and medical devices, indicating a balanced investment strategy [4]

速度达到光速70%的重离子轰击，已经治疗了数千名肿瘤患者；只有米粒大小的神经元细胞，从干 细胞分化出来，已经实现了人工培养；国产高载量核酸合成仪一次能合成30多克高质量核酸，这对于以 纳克为单位的核酸生产已是"极大量级"…… 最快、最小、最高产，在今年中关村论坛期间推出的展览上，除了有机器人的炫技，还有生命科学 领域突破极限的各类"最"新成果集中亮相。 开拓"最终疆域"取得原创成果 以脑科学为例，它被认为是科学研究的"最终疆域"，是生命科学最难以攻克的领域之一。在中关村 论坛中，脑科学领域的重重"禁地"正在"解除封印"。 "研究生命必须要有新的分析工具、观测工具。如果靠购买尖端设备开展研究，那么用的将是别人 早就用过多年的设备，科学家也很难取得原创性科学成果。"在3月29日举办的医学AI创新与发展论坛 上，中国科学院院士、北京大学国家生物医学成像科学中心主任程和平带来了自主研发的仅有2.2克、 能跟着小鼠奔跑的双光子显微镜的研究进展和应用成果。他表示，双光子显微镜能够在动物奔跑时实时 对脑细胞进行成像，已经装机上百台，助力中国团队在孤独症研究、神经韧性研究等方面取得了开创性 成果。 这一脑科学研究的"利器"所 ...

Core Viewpoint - Zhiyun Health (09955) reported a revenue of 3.488 billion RMB for the fiscal year ending December 31, 2024, with a gross profit of 862 million RMB and a stable gross margin of 24.7%, reflecting a year-on-year increase of 0.1 percentage points [1] Financial Performance - The increase in overall gross margin is attributed to the improvement in the gross margin of outpatient solutions, which rose from 14.2% for the year ending December 31, 2023, to 23.1% for the year ending December 31, 2024 [1] - The net profit of the five subsidiaries involved in the divestitures totaled 99.6 million RMB (pre-tax) for the fiscal year ending December 31, 2024 [6] Divestiture Details - On March 30, 2025, Zhiyun Health's subsidiary, Hangzhou Kangsheng Health Management Consulting Co., Ltd., agreed to sell 55% of Zhejiang Qilian Pharmaceutical Co., Ltd. for 33.5164 million RMB [1] - The company also agreed to sell 30% of Jiangsu Xinwange Medical Technology Co., Ltd. for 32 million RMB and 65% of Jiangsu Wandi Biotechnology Co., Ltd. for 3 million RMB [3] - Additionally, 75% of Lianyungang Zhenghe Scientific Instrument Co., Ltd. was sold for 8 million RMB, and 35% of Jiangsu Chengsheng Gene Precision Medical Technology Co., Ltd. was sold for 3 million RMB [4] Strategic Rationale - The divestitures align with the company's long-term strategy focusing on AI-driven SaaS technology advancements and monetizing the P2M (Patient to Manufacturer) pipeline [1] - The decision to divest is driven by strategic and operational considerations, particularly the need to optimize the P2M strategy and integrate AI as part of the company's transformation efforts [4] Market Impact - The five subsidiaries involved in the divestitures are significantly affected by the national medical insurance bureau's procurement policies, which have led to price reductions in their products [5] - The anticipated sixth batch of high-value medical consumables procurement and the eleventh batch of drug procurement by the national medical insurance bureau in 2025 is expected to adversely impact the future revenue, profit, and asset quality of these subsidiaries [5]

涉及总金额6 0 1 . 4 4亿元人民币。 作者 | 私募通 报道 | 决策投资圈 （ID： PEDATAMAX） 清科创业（01945.HK）旗下私募通统计：截至本周五下午，募资、投资、上市和并购共167起事件，涉及总 金额601.44亿人民币。从交易金额来看，本周金额较大事件是：2025年3月27日，华润三九医药股份有限公 司成功受让天士力生物医药产业集团有限公司、天津和悦科技发展合伙企业（有限合伙）、天津康顺科技发 展合伙企业（有限合伙）、天津顺祺科技发展合伙企业（有限合伙）、天津善臻科技发展合伙企业（有限合 伙）等持有的天士力医药集团股份有限公司的28. 0%的股权，作价59.90亿人民币。从交易事件地域分布看， 目前主要分布在广东省、江苏省和浙江省，占比为广东省15.6%，江苏省13.8%，浙江省12 .6%。 更多信息请登录：htt ps://ma x.pe da t a . c n/ 本周新登记股权投资基金管理人共计0家，取消备案登记12家，全年截至目前累计股权投资基金管理人数量 为17家。本周新增备案基金数量为85只，规模总计41 8. 88亿元，本周备案基金募资最多的为南京江宁智慧股 权投 ...